WELLO2
Training with a counter pressure steam breathing device has the potential to improve voice quality, as revealed in a recent pilot study in Finland. A report on the study was published in Journal of Voice, a peer-reviewed publication regarded as the world's premiere journal for voice medicine and research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200517005004/en/
The protocol of another study, now investigating benefits of using WellO2, a unique counter pressure steam breathing device, with patients with chronic obstructive pulmonary symptoms, has been approved by the ethical committee of the University of Tampere. Both studies focus on the effects of the combination of the inspiratory and expiratory muscle training with warm steam.
Voice professionals have found help
Even before the Finnish study came out, various renown voice professionals have been using WellO2 to help with their voice problems. Among the artists is Uriah Heep’s lead singer Bernie Shaw , who has warmly endorsed WellO2 (see link, below).
The aim of the Finnish pilot study was to determine the efficacy of the 4-week breathing exercise intervention on participants with voice symptoms. Six non-smoking women, mean age 49, experiencing voice symptoms made respiratory muscle exercises for a month with counter pressure on both inspiration and expiration and with warm steam. Speech samples were acoustically measured and perceptually analyzed using the GRBAS, the grade, roughness, breathiness, asthenia and strain scale. Afterwards, perceived voice symptoms and self-reported effort in breathing and phonation were analyzed.
Participants: Breathing was significantly less effortful
The total score of the Acoustic Voice Quality Index (AVQI) and some of its subcomponents, namely shimmer and harmonic-to-noise ratio, and the perceptually evaluated grade, roughness, and strain indicated significantly improved voice quality. However, neither the nature or frequency of the experienced voice symptoms nor the perceived phonatory effort changed as the function of intervention. According to the participants, their breathing was significantly less effortful after the intervention, although no significant changes were observed in the objective respiratory measurements with a spirometer.
According to the study, training with the WellO2 device has the potential to improve voice quality. However, the effects of using WellO2 need to be confirmed by further studies with a larger number of participants, the pilot study concluded.
New studies with WellO2 and chronic obstructive pulmonary symptoms
The ethical committee of the University of Tampere recently gave a positive statement for the clinical study of WellO2 with patients with chronic obstructive pulmonary symptoms. The team is testing the effect of WellO2 device for the respiratory muscle exercises that provides counter pressure. There are several hundreds of referred studies on steam inhalation and counter pressure breathing. None have found any severe side effects for using such devices.
Patented WellO2 counter pressure steam breathing device was developed by Hapella Oy, Finland. The device has been available since 2016 as a non-medical device. Over 35 000 devices have been sold in Finland, alone. It is sold both in pharmacies and other stores, like electric commodity store chain of Elgiganten in Sweden and Elkjøp in Norway. Wello2 is available on e-commerce, also at various Amazon e-stores, e.g. in Italy and Germany.
Medical references & links:
https://wello2.com/blogs/news/wello2-counter-pressure-steam-breathing-helps-with-voice-symptoms
View source version on businesswire.com: https://www.businesswire.com/news/home/20200517005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
